Monocarboxylate transporters 1-4 in NSCLC: MCT1 is an independent prognostic marker for survival

• Published in: PloS one 2014-09, Vol.9 (9), p.e105038-e105038
• Main Authors: Eilertsen, Marte, Andersen, Sigve, Al-Saad, Samer, Kiselev, Yury, Donnem, Tom, Stenvold, Helge, Pettersen, Ingvild, Al-Shibli, Khalid, Richardsen, Elin, Busund, Lill-Tove, Bremnes, Roy M
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Angiogenesis; Biology; Biology and Life Sciences; Biomarkers, Tumor; Biopsy; Cancer; Cancer therapies; Carcinoma, Non-Small-Cell Lung - metabolism; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - pathology; Carcinoma, Non-Small-Cell Lung - surgery; Cell Line, Tumor; Cell survival; Clinical medical disciplines: 750; Clinical medicine; Compartments; Ethics; Female; Glycolysis; Homeostasis; Hospitals; Humans; Hypoxia; Immunohistochemistry; Klinisk medisinske fag: 750; Lactic acid; Lung cancer; Lung Neoplasms - metabolism; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Lung Neoplasms - surgery; Male; Medical disciplines: 700; Medical research; Medicine; Medicine and Health Sciences; Medisinske Fag: 700; Metabolism; Middle Aged; Monocarboxylic Acid Transporters - genetics; Monocarboxylic Acid Transporters - metabolism; Muscle Proteins - genetics; Muscle Proteins - metabolism; Neoplasm Staging; Non-small cell lung carcinoma; Oncology; Oncology: 762; Onkologi: 762; Oxidation; Pathology; Prognosis; Proteins; Radiation therapy; Risk Factors; Stromal cells; Stromal Cells - metabolism; Survival; Symporters - genetics; Symporters - metabolism; Tumors; VDP
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0105038

Monocarboxylate transporters (MCTs) 1-4 are lactate transporters crucial for cancers cells adaption to upregulated glycolysis. Herein, we aimed to explore their prognostic impact on disease-specific survival (DSS) in both cancer and tumor stromal cells in NSCLC. Tissue micro arrays (TMAs) were constructed, representing both cancer and stromal tumor tissue from 335 unselected patients diagnosed with stage I-IIIA NSCLC. Immunohistochemistry was used to evaluate the expression of MCT1-4. In univariate analyses; ↓ MCT1 (P = 0.021) and ↑ MCT4 (P = 0.027) expression in cancer cells, and ↑ MCT1 (P = 0.003), ↓ MCT2 (P = 0.006), ↓ MCT3 (P = 0.020) expression in stromal cells correlated significantly with a poor DSS. In multivariate analyses; ↓ MCT1 expression in cancer cells (HR: 1.9, CI 95%: 1.3-2.8, P = 0.001), ↓ MCT2 (HR: 2.4, CI 95%: 1.5-3.9, P